PRLD - Prelude Therapeutics Inc
IEX Last Trade
1.345
-0.005 -0.372%
Share volume: 3,130
Last Updated: Fri 27 Dec 2024 08:30:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.35
-0.01
-0.37%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
12.90%
1 Month
33.33%
3 Months
-33.96%
6 Months
-62.06%
1 Year
-65.26%
2 Year
-69.63%
Key data
Stock price
$1.34
DAY RANGE
$1.35 - $1.46
52 WEEK RANGE
$0.91 - $6.80
52 WEEK CHANGE
-$67.21
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Krishna Vaddi
Region: US
Website: preludetx.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: preludetx.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Recent news